Perbandingan Angiotensin II Receptor Blocker Candesartan vs Termisartan vs Valsartan pada Monitoring Tekanan Darah Pasien Chronic Kidney Disease

Selly Septi Fandinata, Rizky Darmawan

Abstract


 

Hypertension is a health problem that needs to be taken seriously because it is the most powerful killer disease in the world. Blood pressure is a determining factor to achieve and target BP. The recommended antihypertensive guidelines are ACEI, ARB, diuretic, CCB or B-blocker. ARBs have a cardiorenal protective effect. This study aims to compare the effectiveness of blood pressure drugs valsartan, termisartan and candesartan in hypertensive patients with chronic kidney disease. This study was a prospective observational cohort study by measuring blood pressure before and after at the 1st and 6th months and then processed using statistical analysis of the independent t-test and Wilcoxon. The results of this study obtained data as many as 72 patients who met the inclusion criteria consisting of 24 patients (candesartan), 27 patients (termisartan) and 21 patients (valsartan). The candesartan therapy group, the average difference in systolic decline was 18.46±16.14 mmHg and diastolic 2.04±15.16 mmHg with systolic pressure p-value = 0.000, diastolic p value = 0.217. Termisartan therapy had an average difference in systolic pressure reduction of 18.19±12.12 mmHg and diastolic pressure of 9.44±8.01 mmHg with systolic p-value = 0.000 and diastolic p-value = 0.000. The valsartan therapy group averaged a difference in systolic decrease of 0.14±1.2 mmHg, diastolic 2.71±2.84 mmHg with systolic pressure p-value = 0.766 and diastolic p-value = 0.102. So that of the three antihypertensive drugs, the most effective ARB in lowering systolic and diastolic blood pressure is telmisartan

Keywords: blood pressure; termisartan; chronic kidney disease

 

ABSTRAK

 

Hipertensi merupakan masalah kesehatan yang perlu ditangani secara serius karena merupakan penyakit pembunuh paling dahsyat di dunia. Tekanan darah merupakan faktor penentuan agar tercapai dan target TD. Pedoman antihipertensi direkomendasikan yaitu ACEI, ARB, diuretik, CCB atau B-blocker. ARB memiliki efek protektif kardiorenal. Penelitian ini bertujuan untuk mengetahui perbandingan efektifitas tekanan darah obat valsartan, termisartan dan candesartan pada pasien hipertensi dengan chronic kidney disease. Penelitian ini merupakan penelitian kohort pengambilan data secara observasional prospektif dengan mengukur tekanan darah sebelum sesudah pada bulan ke 1 dan ke 6 kemudian diolah menggunakan analisa statistika uji t-independent dan Wilcoxon. Hasil penelitian ini didapatkan data sebanyak 72 pasien yang memenuhi kriteria inklusi terdiri 24 pasien (candesartan), 27 pasien (termisartan) dan 21 pasien (valsartan). Kelompok terapi candesartan, rata-rata selisih penurunan sistolik 18,46±16,14 mmHg dan diastolik 2,04±15,16 mmHg dengan tekanan sistolik nilai p = 0,000, diastolik nilai p = 0,217. Terapi termisartan rata-rata selisih penurunan tekanan sistolik 18,19±12,12 mmHg dan diastolik 9,44±8,01 mmHg dengan sistolik nilai p = 0,000 dan diastolik nilai p = 0,000. Kelompok terapi valsartan rata-rata selisih penurunan sistolik 0,14±1,2 mmHg, diastolik 2,71±2,84 mmHg dengan tekanan sistolik nilai p = 0,766 dan diastolik nilai p = 0,102. Sehingga dari ketiga obat anhipertensi golongan ARB yang paling efektif dalam menurunkan tekanan darah sistolik dan diastolik adalah telmisartan.

Kata kunci: tekanan darah; termisartan; gagal ginjal kronik


Full Text:

PDF


DOI: http://dx.doi.org/10.33846/sf13110

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

___________________________________________________________________________________________________________________________________

Jurnal Penelitian Kesehatan SUARA FORIKES (Journal of Health Research FORIKES VOICE), e-ISSN: 2502-7778, p-ISSN 2086-3098

Volume 1-6 (2010-2015) are available at http://suaraforikes.webs.com)

___________________________________________________________________________________________________________________________________